香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責 ， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明 ， 並 明 確 表 示 ， 概 不 對 因 本 公 告 全 部 或 任 何 部 份 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 補充公告 關連交易 有關對浙江商盟科技有限公司 之 增資事項 1. 引 言 茲提 述 本公 司 日期 為 2026 年 2 月 4 日 的有 關 復星 商 發根 據增 資 協議 認 購商 盟科 技 新增 註 冊資 本的 公 告（「 原公告 」）。除本 公 告另 有 界定 外，本 公告 所 用詞彙的涵義與原公告所界定者相同。本公告旨在就本次增資提供進一步 詳情 。 2. 商 盟 科 技 補 充資 料 商盟 科 技成 立 於 2009 年 8 月 19 日， 主要 透 過商 盟 支付 開展 支 付業 務 ，商 盟支付持有中國支付業務運營相關核心監管資質。商盟科技亦開展跨境支 付相 關 業務，並 持 有 香港 金 錢服 務 經營 者牌 照。商 盟支 付 採 用雙 核 ...

Group 1 - The core viewpoint of the article is that Fidelidade, an insurance company under Fosun International, is expected to have an IPO valuation exceeding €3 billion [1] Group 2 - The IPO valuation of Fidelidade is a significant indicator of the company's market position and potential growth in the insurance sector [1] - The anticipated valuation reflects the increasing interest in insurance companies and their financial performance in the current market environment [1] - This development may attract investors looking for opportunities in the insurance industry, particularly in Europe [1]

Group 1 - The meeting between Jiangsu Province Governor Liu Xiaotao and Fosun International Chairman Guo Guangchang highlights the importance of collaboration in various sectors such as biomedicine, healthcare, culture, tourism, consumption, and finance [1] - Governor Liu emphasized the ongoing efforts to integrate technological and industrial innovation in Jiangsu, aiming to accelerate the development of new productive forces [1] - Fosun International is committed to leveraging its strengths to meet Jiangsu's development needs and enhance cooperation across its business segments, contributing to the province's high-quality development [1] Group 2 - The meeting was attended by Nanjing Mayor Li Zhongjun and Provincial Government Secretary Zhao Jianjun, indicating a high-level engagement between government and business [2]

Summary of the Conference Call for Fosun International Industry and Company Overview - **Company**: Fosun International - **Industry**: Diversified Holdings including healthcare, consumer products, tourism, and insurance Key Points and Arguments 1. **Strategic Focus**: Fosun International is implementing a "slimming down" strategy aimed at systematically enhancing profitability, cash flow generation, and balance sheet health over the next five years, with a gradual increase in shareholder dividends currently maintained at around 20% [2][3][4] 2. **Core Subsidiaries**: The four core subsidiaries of Fosun International are: - **Fosun Health**: Rapid growth in innovative drug revenues with multiple products showing significant potential - **Yuyuan**: Strengthened profitability in fashion jewelry and potential recovery in the liquor business due to consumer recovery - **Fosun Tourism**: Accelerating global resort network expansion with expected profitability improvements - **Fosun Insurance**: Strong premium income growth, leading market share in Portugal [4][6] 3. **Debt Management**: The company aims to reduce interest-bearing debt from a historical peak of 120 billion RMB to below 60 billion RMB, with a target for public market debt to be below 25% [2][8][10] 4. **International Market Performance**: Fosun Pharma has ten products approved in international markets, with strong sales performance and expected significant growth over the next three years, particularly in innovative products like PD-L1 and ADC [5][6] 5. **Yuyuan's Business Transformation**: Yuyuan is actively transforming its brand image and focusing on younger demographics, with new product lines and marketing strategies to align with current consumer trends [2][8] 6. **Capital Allocation**: The company prioritizes capital allocation towards four main industries: health (Fosun Pharma), consumer (Yuyuan and Fosun Tourism), wealth (Portuguese insurance), and manufacturing (Hainan Mining) [4][10] 7. **Operational Efficiency**: The management emphasizes improving operational efficiency and reducing costs, particularly in response to declining profitability in some Yuyuan segments [10][11] 8. **Future Growth Drivers**: Expected growth from innovative drug commercialization, new village expansions, and high-end tourism models is anticipated to contribute to revenue and profit from 2026 to 2027 [11] Other Important Insights - **Market Expansion**: HR Company's gastric cancer surgery phase 3 registration has been successful, with commercialization in over 30 countries, and the U.S. market approval will follow local clinical approval timelines [7] - **IPO Plans**: Fosun Pharma is initiating A-share IPO guidance, which may enhance the valuation of its assets and the overall group [9] - **Collaboration with Clavis Bio**: Fosun Pharma's collaboration involves shared development responsibilities, with specific details to be disclosed publicly [9] This summary encapsulates the essential insights from the conference call, highlighting the strategic direction, financial health, and growth prospects of Fosun International and its subsidiaries.

Core Viewpoint - Fosun International (00656) has announced an investment agreement to acquire a 51.0879% stake in Zhejiang Shangmeng Technology Co., Ltd. by investing RMB 105 million, enhancing its presence in the payment solutions sector [1][2] Group 1: Investment Details - The investment will be made by Fosun's indirect wholly-owned subsidiary, Zhejiang Fosun Commercial Development Co., Ltd. (Fosun Shangfa) [1] - The cash investment of RMB 105 million will be used to subscribe to the newly increased registered capital of Shangmeng Technology [1] - Following the investment, Shangmeng Technology will hold 100% of Shangmeng Payment, which has complete core qualifications and holds necessary payment licenses [1] Group 2: Business Operations - Shangmeng Payment provides a one-stop payment solution for global clients, covering cross-border e-commerce, trade, and travel, as well as domestic payment scenarios in cultural tourism, consumer finance, and new retail [1] - The company has a robust business foundation and good growth potential, supported by its licenses for both domestic and cross-border payment operations [1] Group 3: Strategic Benefits - Through this investment, the company aims to share in the future growth benefits of Shangmeng Technology and leverage synergies between Shangmeng Technology and its own online and offline ecosystems [2]

Group 1 - The core point of the announcement is that Fosun International's subsidiary, Zhejiang Fosun Commercial Development Co., Ltd., will invest RMB 105 million to acquire a 51.0879% stake in Shangmeng Technology through a capital increase agreement [1] - Shangmeng Technology holds 100% of Shangmeng Payment, which possesses essential qualifications including a payment business license and cross-border RMB license, enabling it to operate various payment services [1] - Shangmeng Payment provides a one-stop payment solution for global clients, covering cross-border e-commerce, trade, and travel, as well as domestic payment scenarios in cultural tourism, consumer finance, and new retail, indicating a solid business foundation and growth potential [1] Group 2 - Through this capital increase, the company aims to share in the future growth benefits of Shangmeng Technology and leverage the synergistic effects between Shangmeng Technology and the company's online and offline ecosystem [2]

Core Viewpoint - Fosun International (00656.HK) announced an investment agreement involving its indirect wholly-owned subsidiary, Zhejiang Fosun Commercial Development Co., Ltd., which will invest RMB 105 million in Shangmeng Technology Co., Ltd. to acquire a 51.0879% stake [1] Group 1: Investment Details - Fosun Commercial Development will subscribe to the increased registered capital of Shangmeng Technology for RMB 105 million [1] - The investment will result in Fosun holding a majority stake of 51.0879% in Shangmeng Technology after the capital increase [1] Group 2: Company Background - Shangmeng Technology is a limited liability company registered under Chinese law, primarily engaged in domestic and cross-border payment services [1] - As of the announcement date, Shangmeng Technology is controlled by Mr. Guo, who is the ultimate controlling shareholder of the company [1] Group 3: Subsidiary Information - Shangmeng Technology holds 100% equity in Zhejiang Shangmeng Payment Co., Ltd., which is a payment service provider with essential qualifications such as a payment business license and cross-border RMB license [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責 ， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明 ， 並 明 確 表 示 ， 概 不 對 因 本 公 告 全 部 或 任 何 部 份 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 於 2026 年 2 月 4 日 ，本 公 司之 間 接 全 資附 屬 公司 浙 江復 星商 業 發展 有 限 公 司 （「復 星 商 發 」） 與 浙 江 商 盟 科 技 有 限 公 司 （「 商 盟 科 技 」）、 亞東星辰 創業 投 資有 限 公司（「亞東星辰 」）及 寧 波梅 山 保稅 港 區統 付企 業 管理 合 夥 企業（有 限 合夥 ）（「 寧波統付 」）訂立 一 份《 增資 協 議書 》（「 增資協議 」）。 據此， 復 星 商 發 同 意 以 現 金 人 民 幣 105 百 萬 元 認 購 商 盟 科 技 新 增 註 冊 資 本， 對 應取 得 商盟 科技 增 資 後 51.0879%之 股 權。 上 市 規 則 之 涵義 截至 本 公告 日 ...

| 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00656 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 8,166,663,124 | | 0 | | 8,166,663,124 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 8,166,663,124 | | 0 | | 8,166,663,124 | 足夠公眾持股量的確認(註4) | 根據《主板上市規則》第13.32D(1)條或第19A.28D(1)條 / 《GEM上市規則》第17.37D(1)條或第25.21D(1)條，我們在此確認，就上述所列股份類別而言，截至本月底: | | --- | | ✔ 已符合適用的公眾持股量要求（見下方） | | 未符合適用的公眾持股量要求（見下方） | | 根據《主 ...

Group 1 - The core viewpoint of the report indicates that due to the profit warning from Yuyuan and the latest forecasts for Fosun's other businesses, particularly in the health sector, Fosun International is expected to record a net loss of approximately 778 million yuan in the fiscal year 2025 [1] - Citigroup has lowered its target price for Fosun International from HKD 6.5 to HKD 5.6 while maintaining a "buy" rating [1] - The report suggests that the group's strategy to divest non-core assets through sales or asset securitization could accelerate its deleveraging process and potentially narrow the current 75% discount to net asset value [1] Group 2 - The earnings forecasts for the group have been revised down by 17% to 28% for the next two years [1] - Despite the downward revision, there is potential upside in the group's ability to conduct value-accretive acquisitions in a highly volatile stock market [1]